Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Latar Belakang: Pemeriksaan dan diagnosis kanker prostat (PCa) diperlukan untuk memberikan manajemen optimal pada tahap awal. Meskipun telah dibahas dalam banyak pedoman, implementasi pemeriksaan dan diagnosis PCa di Indonesia masih belum diketahui. Studi ini bertujuan untuk mengevaluasi pola pemeriksaan dan diagnosis PCa di antara urolog Indonesia serta kepatuhan mereka terhadap pedoman. Metode: Studi potong lintang ini dilakukan antara Februari dan Juli 2019. Responden adalah urolog Indonesia yang terdaftar sebagai anggota Perhimpunan Urologi Indonesia (IUA) dan telah berpraktik selama setidaknya enam bulan. Data dikumpulkan menggunakan kuesioner yang dibagikan dalam simposium urologi nasional dan secara elektronik melalui Google Form. Data disajikan secara deskriptif, dan semua data diproses menggunakan SPSS versi 23. Hasil: Dari 458 urolog, 195 (42,6%) memberikan respons lengkap. Sebagian besar responden, 181 (92,8%) urolog, menggunakan pedoman IUA. Di antara 103 (52,8%) responden yang melakukan pemeriksaan, hampir separuh (42,7%) setuju untuk memeriksa pasien yang berusia ≥ 50 tahun atau ≥ 45 tahun dengan riwayat keluarga PCa. Selain itu, 76,8% akan mengulang pemeriksaan setiap tahun, dan 35,6% akan menghentikannya ketika pasien berusia 70 tahun. Pemeriksaan rektal digital (DRE) sering dilakukan untuk pemeriksaan (74,5%), sementara tes antigen spesifik prostat (PSA) hanya dilakukan dalam 52,3% kasus. Tes PSA tersedia di 74,8% rumah sakit. Reseksi transuretral prostat (TURP) masih digunakan oleh 67,2% responden untuk diagnosis. Hanya 52,3% peserta yang menggunakan biopsi prostat transrektal untuk diagnosis, menggunakan anestesi (78,1%) selama prosedur, dan peningkatan kadar PSA (98%) sebagai indikasi. Namun, USG Transrektal (TRUS) hanya tersedia di 49% rumah sakit. Studi ini menemukan bahwa tingkat kepatuhan urolog Indonesia terhadap pedoman adalah 63,3% (9-100%). Kesimpulan: Pemeriksaan dan diagnosis PCa masih bervariasi di antara urolog Indonesia, yang mungkin disebabkan oleh ketersediaan modalitas diagnostik yang berbeda. ......Background: Prostate cancer (PCa) screening and diagnosis are mandatory to deliver optimal management in the early phase. Even though it has been discussed in many guidelines, the implementation of PCa screening and diagnosis in Indonesia remains unknown. This study aims to evaluate the pattern of PCa screening and diagnosis among Indonesian urologists and their adherence to guidelines. Methods: This cross-sectional study was conducted between February and July 2019. Respondents were Indonesian urologists registered as members of the Indonesian Urological Association (IUA) and had already practiced for at least six months. Data were collected using questionnaires, which were distributed at a national urology symposium and electronically via Google Form. Data were presented descriptively, and all data were processed using SPSS version 23. Result: Of 458 urologists, 195 (42.6%) gave full responses. Most of the respondents, 181 (92.8%) urologists, used the IUA guidelines. Among the 103 (52.8%) respondents who performed screening, nearly half (42.7%) agreed to screen patients aged ≥ 50 years or ≥ 45 years with a family history of PCa. Moreover, 76.8% would repeat screening annually, and 35.6% would stop when the patient's age reached 70 years old. Digital rectal examination (DRE) was frequently performed for screening (74.5%), while prostate-specific antigen (PSA) tests were only performed in 52.3% of cases. The PSA test was available in 74.8% of hospitals. Transurethral resection of the prostate (TURP) was still used by 67.2% of respondents for diagnosis. Only 52.3 % of participants used transrectal prostate biopsy for diagnosis, using anesthesia (78.1%) during the procedure, and increased PSA level (98%) as its indication. However, Transrectal Ultrasound (TRUS) was only available in 49% of hospitals. This study found that Indonesian urologist adherence level toward guidelines was 63.3% (9-100%). Conclusion: PCa screening and diagnosis are still varied among Indonesian urologists, which might arise due to the different availability of diagnostic modalities.

Abstrak :
Tujuan penelitian ini untuk menentukan model fungsi sum of exponential (SOE) terbaik dan membandingkan parameter fixed effect, random effect dan Area Under Curve (AUC) yang diperoleh pada NONMEM dan Matlab. Penelitian ini menggunakan data dari 10 pasien kanker prostat yang menerima injeksi ~3 GBq. Setlah diinjeksikan, dilakukan pemeriksaan menggunakan SPECT/CT pada waktu 1, 24, 48, 72, dan 168 jam. Data tersebut di-fitting menggunakan 54 fungsi SOE. Model fungsi terbaik ditentukan dengan kriteria nilai pembobotan Corrected Akaike Information Criterion (AICc). Fungsi terbaik yang dapat mendeskripsikan distribusi biokinetik data pada Organ at Risk (OAR) ditunjukkan fungsi f6f untuk ginjal, fungsi f4c untuk kelenjar ludah, dan fungsi f5g untuk hati. Perbedaan nilai parameter yang di fitting antara NONMEM dan Matlab memiliki nilai yang relatif besar hingga 1070%. Namun, perbedaan AUC pada NONMEM dan Matlab memiliki nilai yang kecil yaitu di bawah 1.5%. ......The purpose of this study was to determine the best sum of exponential (SOE) function model and compare the fixed effect, random effect and Area Under Curve (AUC) parameters obtained in NONMEM and Matlab. This study used data from 10 prostate cancer patients who received ~3 GBq injection. After injection, SPECT/CT was performed at 1, 24, 48, 72, and 168 hours. The data were fitted using 54 SOE functions. The best function model was determined by weighting the Corrected Akaike Information Criterion (AICc). The best function that can describe the biokinetic distribution of data on Organ at Risk (OAR) is shown by the function f6f for kidney, function f4c for salivary gland, and function f5g for liver. The difference in the fitted parameter values between NONMEM and Matlab has a relatively large value of up to 1070%. However, the difference in AUC in NONMEM and Matlab has a small value which is below 1.5%.

Abstrak :
ABSTRAK
Dalam perencanaan terapi teknik lanjut telah diimplementasikan algoritma Anisotropic Analytical Algorithm AAA dan Acuros XB pada perencanaan terapi dengan teknik IMRT dan VMAT. Dalam penelitian ini dimaksudkan untuk memverifikasi simulasi perencanaan terapi dan pemberian dosis IMRT dan VMAT pada kasus kanker prostat dan kanker paru. Verifikasi dosis dilakukan dengan meletakkan TLD 100 LiF rod dan film Gafchromic EBT3 pada fantom Rando Alderson. Evaluasi dosis dilakukan dengan membandingkan analisis dosimetri PTV dan organ at risk menggunakan algoritma Anisotropic Analytical Algorithm AAA dan Acuros XB pada teknik IMRT dan VMAT. Dari hasil penelitian PTV pada kanker prostat algoritma Acuros XB memiliki kualitas perencanaan lebih baik dibandingkan Anisotropic Analytical Algorithm AAA sebesar 1 . Pola yang sama juga diperoleh organ at risk dengan algoritma terbaik diperoleh Acuros XB dengan penyimpangan rata-rata terbesar pada OAR femoral head sebesar 6 . Lebih lanjut PTV pada kanker paru kiri dan kanan memiliki penyimpangan rata-rata lebih kecil pada teknik VMAT. Sementara pada penggunaan algoritma Acuros XB memiliki kualitas perencanaan lebih baik dibandingkan Anisotropic Analytical Algorithm AAA sebesar 0,56 . Pada OAR kasus paru kiri dan kanan tidak terdapat perbedaan yang signifikan dari penggunaan algortima Acuros XB dan Anisotropic Analytical Algorithm AAA dengan rentang deviasi terbesar diperoleh jantung 9.

---

ABSTRACT
In the planning of advanced engineering therapy has been implemented Anisotropic Analytical Algorithm AAA and Acuros XB algorithms on therapy planning with IMRT and VMAT techniques. In this study intended to verify the simulation of therapy planning and dosage of IMRT and VMAT in cases of prostate cancer and lung cancer. Dose verification is done by placing TLD 100 LiF rod and Gafchromic EBT3 film on fantom Rando Alderson. Dose evaluation was done by comparing dosimetry analysis of PTV and organ at risk using Anisotropic Analytical Algorithm AAA and Acuros XB algorithm on IMRT and VMAT techniques. From the results of research PTV on prostate cancer algorithm Acuros XB has better planning quality than Anisotropic Analytical Algorithm AAA of 1 . The same pattern is also obtained by the organ at risk with the best algorithm obtained by Acuros XB with the largest mean deviation on femoral head OAR of 6 . Furthermore, PTV in left and right lung cancer has a smaller mean deviation in VMAT technique. While the use of Acuros XB algorithm has better planning quality than Anisotropic Analytical Algorithm AAA of 0.56 . In the left and right lung OAR cases there was no significant difference from the use of the Acuros XB algorithm and the Anisotropic Analytical Algorithm AAA with the largest deviation range obtained by heart 9 .

Abstrak :
The volume provides an introduction to the concept of active surveillance in oncology in general and prostate cancer specifically. The primary focus is to provide a comprehensive guide to the management of patients on surveillance. The volume covers the many complexities and nuances to this approach including, patient selection, risk assessment, how to overcome 'cancer hysteria' when counseling patients, identifying appropriate triggers for intervention, use of PSA kinetics and MR imaging information, technique and frequency of biopsies, secondary prevention interventions, and the relative roles of surveillance and focal therapy.

Abstrak :
This book provides an exhaustive review of the current state of the art in the management of prostate cancer, from screening to treatment. A particular feature is the emphasis placed on the value of a multidisciplinary approach. The opening chapters address basic aspects including epidemiology, biology, and chemoprevention. The role of individual and mass screening is carefully appraised, and diagnosis, clinical work-up, and the role of active surveillance are discussed in detail. Subsequent chapters are devoted to each of the therapies that may be employed, including open and robotic laparoscopic radical prostatectomy, the various forms of radiation therapy, high-intensity focused ultrasound, cryotherapy, hormonal therapy, and targeted therapies and vaccination. Up-to-date data from clinical trials are included.